Here is the design of a clinical trial:

Official Title: GABA-WHY Study: Deprescription of Gabapentinoids in Medical Inpatients

Included conditions:
- Polypharmacy
- Gabapentin
- Pregabalin

Study Armgroups:
- {'label': 'Usual Medical Care', 'type': 'NO_INTERVENTION', 'description': 'During the control period, patients admitted to the study sites who qualify for the trial will receive a pharmacy medication reconciliation as part of usual medical care. Study participants will be informed that the goal of the trial is to evaluate medication use and medication changes after discharge, but they will not be informed that gabapentinoids are specifically being targeted. Medical staff will not receive specific information about the trial, or particular instructions with regards to deprescription during the control period.'}
- {'label': 'In-Hopsital Patient Educational Brochure and Physician Education about Gabapentinoid Prescription', 'type': 'EXPERIMENTAL', 'description': 'During the intervention period, patients admitted to the study sites who qualify for the trial will receive an in-hospital educational brochure. Additionally, the medical team will attend an educational session about gabapentinoid prescription.', 'interventionNames': ['Other: In-Hopsital Patient Educational Brochure', 'Other: Physician Education about Gabapentinoid Prescription']}

Interventions:
- {'type': 'OTHER', 'name': 'In-Hopsital Patient Educational Brochure', 'description': "The participant's medication list will be identified from the pharmacy database and validated with the participant's best possible medication history taken at time of admission by a pharmacist. Eligibility will be confirmed by the participant's treating medical team with support from the study investigators. Participants who are enrolled during the intervention phase will receive an educational brochure about the risks of chronic gabapentinoid use, and about how to safely discontinue use. The brochure is written using a sixth-grade vocabulary and has been validated in both English and French for comprehension and readability, including for people with mild cognitive impairment.", 'armGroupLabels': ['In-Hopsital Patient Educational Brochure and Physician Education about Gabapentinoid Prescription']}
- {'type': 'OTHER', 'name': 'Physician Education about Gabapentinoid Prescription', 'description': 'An educational session about the purpose of the study and risks of gabapentinoid prescription will be delivered to physicians (staff and medical residents) on each study unit at both sites during the intervention period. The educational session will include a presentation by the chief of the medical service at the monthly teaching rounds, and an electronic message will be sent to all physicians on the medical service. Physicians will also be presented a brief overview of the educational brochure.', 'armGroupLabels': ['In-Hopsital Patient Educational Brochure and Physician Education about Gabapentinoid Prescription']}

Primary Outcomes:
- {'measure': 'Gabapentinoid Discontinuation or Dose Reduction With Intention to Stop', 'description': 'Proportion of study participants with a gabapentinoid prescription stopped or decreased with intention to stop at the time of follow-up', 'timeFrame': '8-weeks post-hospital discharge'}

Please estimate the sample size based on the assumption: 
The sample size calculation allows for a 2-sided type 1 error of 5%, a type 2 error of 20%, and accounts for a 15% loss to follow-up.
Sample sizeThe estimated sample size is 160 participants, with a 1:1 distribution between the intervention and control groups. The control period event rate (gabapentinoid deprescription at 8 weeks postdischarge) is expected to be 13%.15 We calculated the sample size to detect an absolute increase of 20% in deprescription rates (number needed to treat of 5), allowing for a 2-sided type 1 error of 5% and a type 2 error of 20% (132 subjects), and accounting for 15% loss to follow-up, including death in hospital and after discharge (156 subjects, rounded to 160). Given previous trial results showing that educational brochures for benzodiazepines can lead to an absolute increase of 43% in deprescription rates among medical inpatients (number needed to treat of 3),18 an absolute increase in deprescription rates of 20% was thought to be a reasonable target in this trial.